Supplemental Information.docx (37.65 kB)

Supplemental Information: OLIE, ITCC-082: A phase 2 trial of lenvatinib plus ifosfamide and etoposide in relapsed/refractory osteosarcoma.docx

dataset

posted on 2021-08-12, 10:17 authored by Nathalie Gaspar, Quentin Campbell-Hewson, Jie HuangJie Huang, Chinyere E. Okpara, Francisco Bautista

Supplemental Information - Definitions of study endpoints and relevant details

Funding

Eisai Inc.

Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.

History

Usage metrics

Future Oncology

Categories

Cancer therapy (excl. chemotherapy and radiation therapy)

Keywords

lenvatinib chemotherapy ifosfamide etoposide tyrosine kinase inhibitor relapsed-refractory osteosarcoma pediatric adolescent young adult Cancer Therapy (excl. Chemotherapy and Radiation Therapy)

Licence

CC BY-NC-ND 4.0

Exports